Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Liabilities (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Total Liabilities for 10 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 24.2% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 24.2% year-over-year, with the annual reading at $1.7 billion for FY2025, 24.2% up from the prior year.
  • Total Liabilities hit $1.7 billion in Q4 2025 for Ascendis Pharma A, up from $1.4 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.7 billion in Q4 2025 to a low of $230.3 million in Q4 2021.
  • Historically, Total Liabilities has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2023.
  • Biggest five-year swings in Total Liabilities: soared 266.15% in 2022 and later rose 23.95% in 2023.
  • Year by year, Total Liabilities stood at $230.3 million in 2021, then skyrocketed by 266.15% to $843.1 million in 2022, then increased by 23.95% to $1.0 billion in 2023, then skyrocketed by 31.42% to $1.4 billion in 2024, then increased by 24.2% to $1.7 billion in 2025.
  • Business Quant data shows Total Liabilities for ASND at $1.7 billion in Q4 2025, $1.4 billion in Q4 2024, and $1.0 billion in Q4 2023.